{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:32:48Z","timestamp":1791379968599,"version":"4.3.3"},"reference-count":71,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Abstract\nPoor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies represent a minority of patients who may benefit from LAI-AP. Mirror and naturalistic studies generally demonstrate efficacy of LAI-AP on more representative samples, but studies on FEP are scarce.\nAim\nTo describe LAI-AP\u2019s utilization and impact on FEP outcome in a naturalistic setting.\nMethods\nA 3-year longitudinal prospective and retrospective descriptive study of all consecutive admissions from two Early Intervention Services for psychosis (EIS) in Montr\u00e9al, Canada, compared the characteristics and evolution of patients who received LAI-AP for at least 12 months to those who received OAP only.\nResults\nFrom 375 FEP patients included, 26,7% received LAI-AP during their follow-up. They were more likely to have poor prognostic factors (male gender, lower premorbid functioning, homelessness, substance use disorder and schizophrenia spectrum diagnoses). Despite a more severe illness and lower functioning in the LAI-AP group, at admission and study endpoint, clinical and functional improvements were observed.\nConclusion\nEarly prescription of LAI-AP seems beneficial in FEP with poor prognostic factors.<\/jats:p>","DOI":"10.64719\/pb.4577","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"25-61","source":"Crossref","is-referenced-by-count":4,"title":["Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis"],"prefix":"10.64719","volume":"48","author":[{"given":"Sofia","family":"Medrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Abdel-Baki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Stip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bradford Daniel W, Perkins Diana O, Lieberman Jeffrey A. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs. 2003;63:2265\u20132283.","DOI":"10.2165\/00003495-200363210-00001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kane John M, Kishimoto Taishiro, Correll Christoph U. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of clinical epidemiology. 2013;66:S37\u2013S41.","DOI":"10.1016\/j.jclinepi.2013.01.012"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Leclerc Emilie, Noto Cristiano, Bressan Rodrigo A, Brietzke Elisa. Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Revista Brasileira de Psiquiatria. 2015;37:168\u2013176.","DOI":"10.1590\/1516-4446-2014-1539"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Rabinovitch Mark, B\u00e9chard-Evans Laura, Schmitz Norbert, Joober Ridha, Malla Ashok. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. The Canadian Journal of Psychiatry. 2009;54:28\u201335.","DOI":"10.1177\/070674370905400106"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Malla Ashok, Norman Ross, Schmitz Norbert et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological medicine. 2006;36:649\u2013658.","DOI":"10.1017\/S0033291706007379"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Abdel-Baki Amal, Ouellet-Plamondon Clair\u00e9laine, Salvat \u00c9milie, Grar Kawthar, Potvin St\u00e9phane. Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Research. 2017;247:113\u2013119.","DOI":"10.1016\/j.psychres.2016.11.007"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ouellet-Plamondon C, Abdel-Baki A, Salvat \u00c9, Potvin S. Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychological Medicine. 2017:1\u201311.","DOI":"10.1017\/S0033291717000976"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Abdel-Baki Amal, Ouellet-Plamondon Clair\u00e9laine, Malla Ashok. Pharmacotherapy challenges in patients with first-episode psychosis. Journal of affective disorders. 2012;138:S3\u2013S14.","DOI":"10.1016\/j.jad.2012.02.029"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kishimoto Taishiro, Nitta Masahiro, Borenstein Michael, Kane John M, Correll Christoph U. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. The Journal of clinical psychiatry. 2013;74:957\u2013965.","DOI":"10.4088\/JCP.13r08440"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Lafeuille Marie-H\u00e9l\u00e8ne, Dean Jason, Carter Valerie et al. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Current medical research and opinion. 2014;30:1643\u20131655.","DOI":"10.1185\/03007995.2014.915211"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Subotnik Kenneth L, Casaus Laurie R, Ventura Joseph et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA psychiatry. 2015;72:822\u2013829.","DOI":"10.1001\/jamapsychiatry.2015.0270"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Toll Privat Alba, Berge Baquero Daniel, Mane Santacana Anna, Perez Sola Victor. Decreased Incidence of Readmissions in First Episode Psychosis in Treatment with Long-Acting Injectable Antipsychotics. Current Psychopharmacology. 2015;4:52\u201357.","DOI":"10.2174\/2211556004666150918194108"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Tiihonen Jari, Walhbeck Kristian, L\u00f6nnqvist Jouko et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal. 2006;333:224.","DOI":"10.1136\/bmj.38881.382755.2F"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tiihonen Jari, Haukka Jari, Taylor Mark, Haddad Peter M, Patel Maxine X, Korhonen Pasi. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry. 2011;168:603\u2013609.","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tiihonen Jari, Mittendorfer-Rutz Ellenor, Majak Maila et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA psychiatry. 2017;74:686\u2013693.","DOI":"10.1001\/jamapsychiatry.2017.1322"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Fusar-Poli Paolo, Kempton Matthew J, Rosenheck Robert A. Efficacy and safety of second generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. International clinical psychopharmacology. 2013;28:57\u201366.","DOI":"10.1097\/YIC.0b013e32835b091f"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kishi Taro, Oya Kazuto, Iwata Nakao. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Research. 2016;246:750\u2013755.","DOI":"10.1016\/j.psychres.2016.10.053"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kishimoto Taishiro, Robenzadeh Alfred, Leucht Claudia et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia bulletin. 2012:sbs150.","DOI":"10.1093\/schbul\/sbs150"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rosenheck Robert A, Krystal John H, Lew Robert et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine. 2011;364:842\u2013851.","DOI":"10.1056\/NEJMoa1005987"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Bossie Cynthia A, Alphs Larry D, Correll Christoph U. Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. International clinical psychopharmacology. 2015;30:272.","DOI":"10.1097\/YIC.0000000000000082"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nicole L, Abdel-Baki A, Lesage A, Granger B, Stip E, Lalonde P. Study of the follow-up of early psychosis at the Universit\u00e9 de Montr\u00e9al L\u2019\u00c9tude de Suivi des Psychoses \u00c9mergentes de l\u2019Universit\u00e9 de Montr\u00e9al (ESPEUM): context, objectives and methodology. Sante mentale au Quebec. 2006;32:317\u2013331.","DOI":"10.7202\/016523ar"},{"key":"ref22","unstructured":"Early Psychosis Guidelines Writing Group, National Support Program EPPIC. Australian clinical guidelines for early psychosis. Melbourne: Orygen, The National Centre of Excellence in Youth Mental Health2nd ed; 2016."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kay Stanley R, Flszbein Abraham, Opfer Lewis A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin. 1987;13:261.","DOI":"10.1093\/schbul\/13.2.261"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Addington Donald, Addington Jean, Schissel Bernard. A depression rating scale for schizophrenics. Schizophrenia research. 1990;3:247\u2013251.","DOI":"10.1016\/0920-9964(90)90005-R"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Heinrichs Douglas W, Hanlon Thomas E, Carpenter William T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia bulletin. 1984;10:388\u2013398.","DOI":"10.1093\/schbul\/10.3.388"},{"key":"ref26","unstructured":"Drake RE, Mueser KT, McHugo GJ. Clinician rating scales: alcohol use scale (AUS), drug use scale (DUS), and substance abuse treatment scale (SATS) Outcomes assessment in clinical practice. 1996:113\u2013116."},{"key":"ref27","unstructured":"Bernstein David P, Fink Laura. Childhood trauma questionnaire: A retrospective self-report: Manual. Harcourt Brace & Company; 1998."},{"key":"ref28","unstructured":"American Psychiatric Association, others. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) Washington, DC: 2000. Author."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Roy M-A, Lanct\u00f4t G, Macute C et al. Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. American Journal of Psychiatry. 1997","DOI":"10.1176\/ajp.154.12.1726"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Goldman Howard H, Skodol Andrew E, Lave Tamara R. Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry. 1992;149:1148\u20131156.","DOI":"10.1176\/ajp.149.9.1148"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hall Richard CW. Global assessment of functioning: a modified scale. Psychosomatics. 1995;36:267\u2013275.","DOI":"10.1016\/S0033-3182(95)71666-8"},{"key":"ref32","unstructured":"Padhi Ashwini, Fineberg Naomi. Clinical Global Impression Scales in Encyclopedia of Psychopharmacology. 2010 Springer;:303\u2013303."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Haddad Peter M, Brain Cecilia, Scott Jan. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures. 2014;5:43\u201362.","DOI":"10.2147\/PROM.S42735"},{"key":"ref34","unstructured":"IBM Corporation. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY, USA: IBM Corporation. 2011"},{"key":"ref35","unstructured":"Abdel-Baki Amal, L\u00e9vesque Isabelle-Sarah, Ouellet-Plamondon Clairelaine, Nicole Luc. Should we care about homelessness in first episode psychosis?: impact on outcome. Early Intervention in Psychiatry. 2014;8:85."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shi Lizheng, Ascher-Svanum Haya, Zhu Baojin et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services. 2007","DOI":"10.1176\/appi.ps.58.4.482"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Rabinowitz Jonathan, De Smedt Goedele, Harvey Philip D, Davidson Michael. Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. American Journal of Psychiatry. 2002;159:2021\u20132026.","DOI":"10.1176\/appi.ajp.159.12.2021"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Rabinowitz Jonathan, Harvey Philip D, Eerdekens Marielle, Davidson Michael. Premorbid functioning and treatment response in recent-onset schizophrenia. The British Journal of Psychiatry. 2006;189:31\u201335.","DOI":"10.1192\/bjp.bp.105.013276"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Strous Rael D, Alvir Jose Ma J, Robinson Delbert et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophrenia Bulletin. 2004;30:265.","DOI":"10.1093\/oxfordjournals.schbul.a007077"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Emsley Robin, Oosthuizen Petrus, Koen Liezl, Niehaus Dana JH, Medori Rossella, Rabinowitz Jonathan. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clinical therapeutics. 2008;30:2378\u20132386.","DOI":"10.1016\/j.clinthera.2008.12.020"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bhanji Nadeem H, Chouinard Guy, Margolese Howard C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology. 2004;14:87\u201392.","DOI":"10.1016\/S0924-977X(03)00109-3"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Fenton Wayne S, Blyler Crystal R, Heinssen Robert K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia bulletin. 1997;23:637\u2013651.","DOI":"10.1093\/schbul\/23.4.637"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Rossi Giuseppe, Frediani Sonia, Rossi Roberta, Rossi Andrea. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations BMC. psychiatry. 2012;12:122.","DOI":"10.1186\/1471-244X-12-122"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Cassidy Clifford M, Rabinovitch Mark, Schmitz Norbert, Joober Ridha, Malla Ashok. A comparison study of multiple measures of adherence to antipsychotic medication in firstepisode psychosis. Journal of clinical psychopharmacology. 2010;30:64\u201367.","DOI":"10.1097\/JCP.0b013e3181ca03df"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hargarter L, Bergmans P, Cherubin P, Schreiner A. Early schizophrenia patients treated with once-monthly paliperidone palmitate over a 12-month period-a retrospective observational study. European Psychiatry. 2016;33:S251.","DOI":"10.1016\/j.eurpsy.2016.01.637"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Bret P, Heil M, Queuille E, Bret M-C, Pic R\u00e9seau. Enqu\u00eate des prescriptions de risp\u00e9ridone injectable \u00e0 lib\u00e9ration prolong\u00e9e dans neuf centres hospitaliers du r\u00e9seau PIC. L\u2019Enc\u00e9phale. 2011;37:S58\u2013S65.","DOI":"10.1016\/j.encep.2010.04.001"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"G\u00e1ndara Jes\u00fas, San Molina Luis, Rubio Gabriel, Rodriguez-Morales Alexander, Hidalgo Borrajo Rebeca, Bur\u00f3n Jos\u00e9 Antonio. Experience with injectable long-acting risperidone in longterm therapy after an acute episode of schizophrenia: the SPHERE Study. Expert review of neurotherapeutics. 2009;9:1463\u20131474.","DOI":"10.1586\/ern.09.96"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Wheeler Amanda, Vanderpyl J, Carswell C, Stojkovic M, Robinson E. Explicit review of risperidone long-acting injection prescribing practice. Journal of clinical pharmacy and therapeutics. 2011;36:651\u2013663.","DOI":"10.1111\/j.1365-2710.2010.01219.x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Brissos Sofia, Veguilla Miguel Ruiz, Taylor David, Balanz\u00e1-Martinez Vicent. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic advances in psychopharmacology. 2014;4:198\u2013219.","DOI":"10.1177\/2045125314540297"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kim Borah, Lee Sang-Hyuk, Yang Yen Kuang, Park Jong-Il, Chung Young-Chul. Longacting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophrenia research and treatment. 2012:2012.","DOI":"10.1155\/2012\/560836"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Peuskens Joseph, Olivares JM, Pecenak J et al. Treatment retention with risperidone longacting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Current medical research and opinion. 2010;26:501\u2013509.","DOI":"10.1185\/03007990903488670"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Verdoux H, Lengronne J, Liraud F et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica. 2000;102:203\u2013210.","DOI":"10.1034\/j.1600-0447.2000.102003203.x"},{"key":"ref53","unstructured":"Sant\u00e9 Canada. Renseignement sur le produit Risperdal Consta de Sant\u00e9 Canada. [Wednesday, March 29, 2017]; https:\/\/produits-sante.canada.ca\/dpd-bdpp\/info.do?code=74091&lang=en2017."},{"key":"ref54","unstructured":"Sant\u00e9 Canada. Renseignement sur le produit Invega Sustenna de Sant\u00e9 Canada. [Wednesday, March 29, 2017]; https:\/\/produits-sante.canada.ca\/dpd-bdpp\/info.do?code=83941&lang=fr2017."},{"key":"ref55","unstructured":"Sant\u00e9 Canada. Renseignement sur le produit Abilify Maintena de Sant\u00e9 Canada. [Wednesday, March 29, 2017]; https:\/\/produits-sante.canada.ca\/dpd-bdpp\/info.do?code=90545&lang=fr2017."},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Emsley Robin, Oosthuizen Petrus, Koen Liezl, Niehaus Dana JH, Medori Rossella, Rabinowitz Jonathan. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. International clinical psychopharmacology. 2008;23:325\u2013331.","DOI":"10.1097\/YIC.0b013e32830c2042"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Hargarter L, Bergmans P, Cherubin P, Schreiner A. Clinical and functional response to paliperidone palmitate in early schizophrenia-A retrospective observational study in newly diagnosed patients treated over a 12-month period. European Psychiatry. 2016;33:S250\u2013S251.","DOI":"10.1016\/j.eurpsy.2016.01.636"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Malla Ashok, Chue Pierre, Jordan Gerald et al. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clinical schizophrenia & related psychoses. 2016;9:198\u2013208.","DOI":"10.3371\/CSRP.MACH.061213"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Schreiner Andreas, Aadamsoo Kaire, Altamura A Carlo et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia research. 2015;169:393\u2013399.","DOI":"10.1016\/j.schres.2015.08.015"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Carpenter JR, William T, Strauss John S. The Prediction of Outcome in Schizophrenia IV: Eleven-Year Follow-Up of the Washington IPSS Cohort. The Journal of nervous and mental disease. 1991;179:517\u2013525.","DOI":"10.1097\/00005053-199109000-00001"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Amminger G Paul, Henry Lisa P, Harrigan Susy M et al. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophrenia research. 2011;131:112\u2013119.","DOI":"10.1016\/j.schres.2011.06.009"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"McGorry Patrick D, Edwards Jane, Mihalopoulos Cathrine, Harrigan Susan M, Jackson Henry J. EPPIC: an evolving system of early detection and optimal management. Schizophrenia bulletin. 1996;22:305.","DOI":"10.1093\/schbul\/22.2.305"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Carswell Christopher, Wheeler Amanda, Vanderpyl Jane, Robinson Elizabeth. Comparative Effectiveness of Long-Acting Risperidone in New Zealand. Clinical drug investigation. 2010;30:777\u2013787.","DOI":"10.2165\/11537680-000000000-00000"},{"key":"ref64","unstructured":"Lachaine Jean, Lapierre Marie-Eve, Abdalla Nadine, Rouleau Alice, Stip Emmanuel. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2015;60:S40."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Correll Christoph U, Citrome Leslie, Haddad Peter M et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. The Journal of clinical psychiatry. 2016;77:1.","DOI":"10.4088\/JCP.15032su1"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Galletly Cherrie, Castle David, Dark Frances et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry. 2016;50:410\u2013472.","DOI":"10.1177\/0004867416641195"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca P-M. Recommandations Formalis\u00e9es d\u2019Experts de l\u2019AFPBN: prescription des neuroleptiques et antipsychotiques d\u2019action prolong\u00e9e. L\u2019Enc\u00e9phale. 2013;39:189\u2013203.","DOI":"10.1016\/S0013-7006(13)70121-0"},{"key":"ref68","unstructured":"National Institute for Clinical Excellence (NICE) Psychosis and schizophrenia in adults: prevention and management; National Clinical Practice Guidelines Number CG178. [November 15, 2016]; https:\/\/www.nice.org.uk\/guidance\/cg178\/chapter\/1-Recommendations#first-episode-psychosis-2 2014."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Azorin J-M. Guidelines sur les antipsychotiques atypiques d\u2019action prolong\u00e9e (APAPs) dans les premiers \u00e9pisodes psychotiques. L\u2019Enc\u00e9phale. 2013;39:S121\u2013S123.","DOI":"10.1016\/S0013-7006(13)70107-6"},{"key":"ref70","unstructured":"Gardner Kristen N, Nasrallah Henry A. Rationale and Evidence for Nonstandard First-Line Treatments for Schizophrenia: Consider Long-Acting Injectable Antipsychotics; Use Clozapine as Second-or Third-Line Therapy. Only Current Psychiatry. 2015;14:33."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Stip Emmanuel, Abdel-Baki Amal, Bloom David, Grignon Sylvain, Roy Marc-Andr\u00e9. Les antipsychotiques injectables \u00e0 action prolong\u00e9e: avis d\u2019experts de l\u2019Association des m\u00e9decins psychiatres du Qu\u00e9bec. The Canadian Journal of Psychiatry. 2011;56:367\u2013376.","DOI":"10.1177\/070674371105600608"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:34:38Z","timestamp":1791315278000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/three-year-naturalistic-study-on-early-use-of-long-acting-injectable-antipsychotics-in-first-episode-psychosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4577","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}